61.00p-0.50 (-0.81%)21 May 2024, 09:35
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Tissue Regenix Group PLC Fundamentals

Company NameTissue Regenix Group PLCLast Updated2024-05-21
Shares in Issue70.574 mMarket Cap£43.05 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-$0.02EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.2173Debt Equity Ratio0.2903
Asset Equity Ratio1.4731Cash Equity Ratio0.1584
Quick Ratio1.7595Current Ratio4.03
Price To Book Value1.8288ROCE0

Tissue Regenix Group PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Tissue Regenix Group PLC Company Financials

Tangible Assets$9.02 m$8.94 m$9.10 m
Intangible Assets$15.13 m$15.06 m$15.06 m
Total Fixed Assets$24.15 m$24.00 m$24.16 m
Stocks$10.36 m$10.88 m$9.72 m
Debtors$3.68 m$4.78 m$4.02 m
Cash & Equivalents$4.65 m$5.95 m$7.71 m
Other Assets000
Total Assets$43.24 m$46.04 m$46.22 m
Creditors within 1 year$4.74 m$6.64 m$4.36 m
Creditors after 1 year$9.15 m$8.99 m$8.47 m
Other Liabilities000
Total Liabilities$13.89 m$15.64 m$12.83 m
Net assets$29.36 m$30.40 m$33.39 m
Called up share capital$91,000.00$9.17 m$9.16 m
Share Premium$134.25 m$134.18 m$134.17 m
Profit / Loss-$1.67 m-$2.83 m-$5.14 m
Other Equity$30.15 m$31.25 m$34.34 m
Preference & Minorities-$795,000.00-$851,000.00-$950,000.00
Total Capital Employed$29.36 m$30.40 m$33.39 m
Debt Ratio$0.22$0.21$0.19
Assets / Equity1.47311.47311.4731
Cash / Equity0.15840.15840.1584
Cash Flow202320222021
Cash from operating activities$1.04 m-$1.29 m-$2.98 m
Cashflow before financing-$472,000.00-$384,000.00-$3.17 m
Increase in Cash-$1.31 m-$1.47 m-$5.21 m
Turnover$29.49 m$24.48 m$19.75 m
Cost of sales$15.45 m$13.22 m$11.27 m
Gross Profit$14.04 m$11.26 m$8.48 m
Operating Profit-$394,000.00-$2.01 m-$4.38 m
Pre-Tax profit-$1.67 m-$2.83 m-$5.14 m

Tissue Regenix Group PLC Company Background

ActivitiesTissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Itsproduct portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
Latest Interim Date5 Sep 2023
Latest Fiscal Year End Date19 Mar 2024

Tissue Regenix Group PLC Directors

2024-03-19Dr. Trevor Michael PhillipsNon-Executive Director
2013-05-13Mr. Alan John AubreyNon-Executive Director
2013-02-11Mr. Michael Anthony BrethertonNon-Executive Director
2010-06-03Professor William Graham Richards, CBENon-Executive Director
2017-01-06Mr. Ian David JeffersonExecutive Director,Chief Financial Officer and Co Sec
2024-03-19Mr. Jonathan Martin GlennNon-Executive Director,Chairman
2015-02-26Dr. Alison Margaret FieldingNon-Executive Director
2020-03-20Mr. John Andrew Walter SamuelExecutive Director,Chairman
2018-04-27Mr. Anthony Ruben OdellExecutive Director,Chief Executive Officer
2020-12-04Mr. Alan Jonathan Richard MillerNon-Executive Director
2008-01-31Mr. David Robert NorwoodNon-Executive Director
2009-01-31Professor Stephen Graham Davies MA,DPhil,DSc,CChem,MRSCNon-Executive Director
2020-12-04Mr. Randeep Singh Grewal Non-Executive Director
2019-08-01Mr. Steven Ashley CouldwellExecutive Director,Chief Executive Officer
2024-03-19Professor Shervanthi Homer-VanniasinkamNon-Executive Director
2018-04-27Mr. Paul John DevlinExecutive Director,Group Finance Director and Company Secretary
2020-11-17Mr. Gareth Hywel JonesExecutive Director,Interim Chief Executive Officer
2024-03-19Mr. Daniel Ray LeeExecutive Director,Chief Executive Officer
2024-03-19Mr. Brian PhillipsNon-Executive Director
2024-03-19Mr. David Claiborne CockeExecutive Director,Chief Financial Officer

Tissue Regenix Group PLC Contact Details

Company NameTissue Regenix Group PLC
AddressUnit 1 & 2, Astley Way, Swillington, Astley Lane Industrial Estate, Leeds, LS26 8XT

Tissue Regenix Group PLC Advisors

Financial PR AdviserFTI Consulting Inc
Phone+44 2078313113
Fax+44 2030770599
Nominated AdviserJefferies Hoare Govett
Phone(020) 7029 8000
Fax(020) 7029 8010
StockbrokerJefferies Hoare Govett
Phone+44 2070298000
Fax+44 2070298010
Phone+44 1132313000
Fax+44 1132313200
SolicitorDLA Piper LLP
Phone(0)8700 111 111
Fax(0) 113 369 2949
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342